# Corvidia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corvidia-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.corvidiatx.com
- Total disclosed funding: $86M
- Latest round: Series B (Apr 25, 2018)
- Investors on record: 8

## About

Corvidia Therapeutics, Inc. focuses on developing innovative therapies for cardiovascular diseases, harnessing advanced biotechnology to improve patient outcomes and enhance health care solutions.Corvidia Therapeutics, Inc. specializes in the development of novel therapies targeting cardiovascular diseases. Founded in 2015 and headquartered in Waltham, US, the company has successfully completed 4 deals, including a significant TRADE SALE in June 2020 when Novo Nordisk A/S acquired the company for an upfront payment of USD 725 mn. The total amount raised by the company reached USD 725 mn, with future potential depending on sales and regulatory milestones. The current CEO, Marc de Garidel, has a history of leading biotech ventures.Corvidia Therapeutics, Inc. offers a range of biopharmaceutical products aimed at treating cardiovascular conditions. The company's lead therapeutic candidates are designed to address unmet needs in cardiovascular care, promoting better health outcomes through innovative treatment solutions tailored to patient requirements. Their research and development efforts focus on leveraging advanced technologies to create effective and safe medication alternatives.Revenue generation for Corvidia Therapeutics, Inc. primarily arises from strategic partnerships and licensing agreements related to their therapeutic products. The company generates income through upfront payments and potential royalties based on product performance in the market, although specific pricing plans are not publicly disclosed. Their successful collaborations and product advancements contribute to a sustainable revenue model aligned with their therapeutic offerings.In light of the recent acquisition by Novo Nordisk A/S, Corvidia Therapeutics, Inc. is poised to leverage additional resources for advancing its product pipeline. The company plans to further develop its therapies for cardiovascular diseases, with a focus on future product launches that have not been specified yet. The funding from the TRADE SALE will support ongoing research and development, enabling the company to expand into new therapeutic areas and possibly new geographical markets as determined by strategic initiatives.

## Funding rounds

- Series B, Apr 25, 2018, $60M — Sofinnova Partners, HBM Partners, Venrock, Apple Tree Partners, Andera, MedImmune, Inc., Cormorant Asset Management, Fresenius Medical Care Ventures
- Series A, Feb 17, 2016, $26M — Sofinnova Partners, Apple Tree Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Andera — Series B
- MedImmune, Inc. — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Fresenius Medical Care Ventures (https://capitalatlas.ai/funds/fresenius-medical-care-ventures) — Series B